

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/579,125
Filing Date	31 July 2007
First Named Inventor	David James
Group Art Unit	1641
Examiner Name	Not yet assigned
Attorney Docket Number	42-000500US
Date Submitted	September 24, 2007

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	1	WO	2004/055181	A1	Garvan Institute of Medical Research	07-01-2004		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	2	ABU-ELHEIGA ET AL. (2003) "Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets," <i>PNAS</i> , 100(18):10207-10212.	
	3	CHIUSAROLI ET AL. (2003) "Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones," <i>Developmental Biology</i> , 261:537-547.	
	4	FARESE (2002) "Function and dysfunction of aPKC isoforms for glucose transport in insulin-sensitive and insulin-resistant states," <i>Am. J. Physiol. Endocrinol. Metab.</i> , 283(1):E1-11.	
	5	MOLERO ET AL. (2004) "c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action," <i>J. Clinical Investigation</i> , 114(9):1326-1333.	
	6	GRIFFITHS ET AL. (2003) "Cbl-3-deficient mice exhibit normal epithelial development," <i>Molecular and Cellular Biology</i> , 23(21):7708-7718.	
	7	JOAZEIRO ET AL. (1999) "The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase," <i>Science</i> , 286(8):309-312.	
	8	KHAN AND PESSIN (2002) "Insulin regulation of glucose uptake: a complex interplay of intracellular signaling pathways," <i>Diabetologia</i> , 45:1475-1483.	
	9	LIU ET AL. (2003) "The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport," <i>J. Biological Chemistry</i> , 278(38):36754-36762.	
	10	MELIKOVA ET AL. (2003) "Cbl--a polyfunctional regulator of cellular processes," <i>Tsitologiia</i> , 45(11):1134-1148. Abstract only available. <i>PubMed</i> .	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>10/579,125</b>
	Filing Date	<b>31 July 2007</b>
	First Named Inventor	<b>David James</b>
	Group Art Unit	<b>1641</b>
	Examiner Name	<b>Not yet assigned</b>
	Attorney Docket Number	<b>42-000500US</b>
	Date Submitted	<b>September 24, 2007</b>

	11	MURPHY ET AL. (1998) "Tissue hyperplasia and enhanced T-cell signaling via ZAP-70 in c-Cbl deficient mice," <i>Molecular and Cellular Biology</i> , 18(8):4872-4882.	
	12	MUSI ET AL. (2002) "Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes," <i>Diabetes</i> , 51(7):2074-2081.	
	13	SOHN ET AL. (2003) "Cbl-b negatively regulates B cell antigen receptor signaling in mature B cells through ubiquitination of the tyrosine kinase Syk," <i>J. Experimental Medicine</i> , 197(11):1511-1524.	
	14	VOLLENWEIDER (2003) "Insulin resistant states and insulin signaling," <i>Clin. Chem. Lab. Med.</i> , 41(9):1107-1119.	
	15	WINDER ET AL. (2000) "Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle," <i>J. Appl. Physiol.</i> , 88:2219-2226.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.